1801 — Innovent Biologics Share News
0.000.00%
Last trade - 00:00- HK$150.85bn
- HK$130.09bn
- CNY13.04bn
Brief: Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology
Brief: Innovent Biologics Posts FY Total Product Revenue RMB11.9 Billion
Brief: Innovent Biologics Says Tabosun Receives NMPA Approval For Colon Cancer Treatment
Brief: Innovent Biologics Says Pecondle Receives Approval From China's NMPA For Plaque Psoriasis
Brief: Innovent Biologics Says Mazdutide 9Mg Application Accepted For Review By China's NMPA
Innovent Biologics climbs on inclusion in Hang Seng Index
Chinese doctors call for insurance coverage for weight-loss drugs
Brief: Innovent Biologics's Q3 Total Product Revenue Exceeds RMB3.3 Billion
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
China's Innovent signs cancer therapy deal with Japan's Takeda (updated)
Commercialize It In U.S.
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
Analysis: Innovent's weight-loss drug highlights China challenge for Novo, Lilly
Brief: Innovent Announces Mazdutide Received Approval From China's Nmpa For Glycemic Control In Adults With Type 2 Diabetes
Brief: Innovent Biologics Says Mazdutide Approved By China's NMPA
Brief: Fangzhou Launches “Xingshi” LLM, Says in Innovent, Otsuka Tie-up
Brief: Innovent Biologics Logs H1 Adjusted Net Income RMB 1,213.2 Mln
Brief: Innovent Biologics Reports RMB5.2 Billion Total Product Revenue In H1 2025
Live Markets: Chinese biotech licensing deals draw U.S. interest despite modest size, Macquarie says